RxDoctor Payments Data

David Ehrhardt, DO

Neurology · Caledonia, MINPI 1710255575

Payments from drug & device makers

$40,055in general payments, 2019–2025

Across 122 payments — averaging $328.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$39K
  • Supernus Pharmaceuticals, Inc.$374
  • Biogen$272
  • Amgen$265
  • Sanofi$200
  • Pfizer$154
  • plus $166 from 4 others

What the payments were for

  • Consulting fees$4001%
  • Speaking & faculty fees$36,62091%
  • Travel & lodging$7922%
  • Food & beverage$2,1885%
  • Education$550%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,055 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$30,976
Medicare patients
116
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5019$126,812
Emgality PenGalcanezumab-Gnlm140$95,778
Nurtec OdtRimegepant Sulfate26$26,395
Ajovy AutoinjectorFremanezumab-Vfrm15$16,585
QuliptaAtogepant13$14,619
UbrelvyUbrogepant11$10,790
Aimovig AutoinjectorErenumab-Aooe11$9,489
Dimethyl Fumarate11$8,799
Carbidopa-LevodopaCarbidopa/Levodopa98$5,008
Lacosamide43$4,250
Propranolol Hcl ErPropranolol Hcl77$3,815
Lamotrigine ErLamotrigine12$3,230
Memantine Hcl96$1,902
Gabapentin114$1,709
Duloxetine Hcl57$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$154$26,39526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Caledonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →